{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "10934161", "DateCompleted": {"Year": "2000", "Month": "08", "Day": "23"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0002-9440", "JournalIssue": {"Volume": "157", "Issue": "2", "PubDate": {"Year": "2000", "Month": "Aug"}}, "Title": "The American journal of pathology", "ISOAbbreviation": "Am J Pathol"}, "ArticleTitle": "Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.", "Pagination": {"StartPage": "587", "EndPage": "596", "MedlinePgn": "587-96"}, "Abstract": {"AbstractText": ["MDM2, a critical element of cellular homeostasis mechanisms, is involved in complex interactions with important cell-cycle and stress-response regulators including p53. The mdm2-P2 promoter is a transcriptional target of p53. The aim of this study was to determine the association between mdm2-P2 transcripts and the status of the p53 gene in betel- and tobacco-related oral squamous cell carcinomas (SCCs) to understand the mechanism of deregulation of MDM2 and p53 expression and their prognostic implications in oral tumorigenesis. Elevated levels of MDM2 proteins were observed in 11 of 25 (44%) oral hyperplastic lesions, nine of 15 (60%) dysplastic lesions, and 71 of 100 (71%) SCCs. The intriguing feature of the study was the identification and different subcellular localization of three isoforms of MDM2 (ie, 90 kd, 76 kd, and 57 kd) in oral SCCs and their correlation with p53 overexpression in each tumor. The hallmark of the study was the detection of mdm2-P2 transcripts in 12 of 20 oral SCCs overexpressing both MDM2 and p53 proteins while harboring wild-type p53 alleles. Furthermore, mdm2 amplification was an infrequent event in betel- and tobacco-associated oral tumorigenesis. The differential compartmentalization of the three isoforms of MDM2 suggests that each has a distinct function, potentially in the regulation of p53 and other gene products implicated in oral tumorigenesis. In conclusion, we report herein the first evidence suggesting that enhanced translation of mdm2-P2 transcripts (S-mdm2) may represent an important mechanism of overexpression and consequent stabilization and functional inactivation of wild-type p53 serving as an adverse prognosticator in betel- and tobacco-related oral cancer. The clinical significance of the functional inactivation of wild-type p53 by MDM2 is underscored by the significantly shorter median disease-free survival time (16 months) observed in p53/MDM2-positive cases as compared to those which did not show co-expression of these proteins (median time, 26 months; P = 0.02)."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Departments of Biochemistry and Pathology and the Surgical Oncology Unit, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. rralhan@medinst.ernet.in"}], "Identifier": [], "LastName": "Ralhan", "ForeName": "R", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Sandhya", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Meera", "ForeName": "M", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Bohdan", "ForeName": "W", "Initials": "W"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Nootan", "ForeName": "S K", "Initials": "SK"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Am J Pathol", "NlmUniqueID": "0370502", "ISSNLinking": "0002-9440"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "DNA, Neoplasm"}, {"RegistryNumber": "0", "NameOfSubstance": "Nuclear Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Isoforms"}, {"RegistryNumber": "0", "NameOfSubstance": "Proto-Oncogene Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Messenger"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Protein p53"}, {"RegistryNumber": "EC 2.3.2.27", "NameOfSubstance": "MDM2 protein, human"}, {"RegistryNumber": "EC 2.3.2.27", "NameOfSubstance": "Proto-Oncogene Proteins c-mdm2"}, {"RegistryNumber": "EC 3.1.-", "NameOfSubstance": "Ribonucleases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Areca"}, {"QualifierName": [], "DescriptorName": "Blotting, Northern"}, {"QualifierName": [], "DescriptorName": "Blotting, Southern"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "DNA, Neoplasm"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Immunohistochemistry"}, {"QualifierName": [], "DescriptorName": "In Situ Hybridization"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["chemistry", "metabolism", "pathology"], "DescriptorName": "Mouth"}, {"QualifierName": ["chemically induced", "genetics", "pathology"], "DescriptorName": "Mouth Neoplasms"}, {"QualifierName": [], "DescriptorName": "Nuclear Proteins"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Plants, Toxic"}, {"QualifierName": ["genetics"], "DescriptorName": "Promoter Regions, Genetic"}, {"QualifierName": ["genetics"], "DescriptorName": "Protein Isoforms"}, {"QualifierName": ["analysis", "genetics"], "DescriptorName": "Proto-Oncogene Proteins"}, {"QualifierName": [], "DescriptorName": "Proto-Oncogene Proteins c-mdm2"}, {"QualifierName": ["drug effects", "genetics", "metabolism"], "DescriptorName": "RNA, Messenger"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ribonucleases"}, {"QualifierName": [], "DescriptorName": "Survival Analysis"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Nicotiana"}, {"QualifierName": ["drug effects"], "DescriptorName": "Transcription, Genetic"}, {"QualifierName": ["genetics"], "DescriptorName": "Tumor Suppressor Protein p53"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Oliner JD, Kinzler KW, Meltzer PS, George D, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83", "ArticleIdList": ["1614537"]}, {"Citation": "Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245", "ArticleIdList": ["1535557"]}, {"Citation": "Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and mdm2 amplification in human soft tissues sarcomas. Cancer Res 1993, 53:2231-2234", "ArticleIdList": ["8387391"]}, {"Citation": "Reifenberger G, Liu L, Ichimura K, Schmidt EF, Collins VP: Amplification and overexpression of the mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993, 53:2736-2739", "ArticleIdList": ["8504413"]}, {"Citation": "Farkharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in mouse tumor cell line. EMBO J 1991, 10:1565-1569", "ArticleIdList": ["PMC452821", "2026149"]}, {"Citation": "Finlay CA: The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993, 13:301-306", "ArticleIdList": ["PMC358909", "8417333"]}, {"Citation": "Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993, 8:3411-3416", "ArticleIdList": ["8247544"]}, {"Citation": "Barak Y, Gottlieb E, Juven-Gershon T, Oren M: Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994, 8:1739-1749", "ArticleIdList": ["7958853"]}, {"Citation": "Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M: A functional p53-responsive intronic promoter is contained within the human mdm-2 gene. Nucleic Acid Res 1995, 23:2584-2592", "ArticleIdList": ["PMC307078", "7651818"]}, {"Citation": "Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ: Identification and characterization of multiple MDM2 proteins and MDM2 -p53 protein complexes. Oncogene 1993, 8:2353-2360", "ArticleIdList": ["7689721"]}, {"Citation": "Dazard JE, Augias D, Neel H, Mils V, Marechal V, Basset-Seguin N, Piette J: MDM2 protein is expressed in different layers of normal human skin. Oncogene 1997, 14:1123-1128", "ArticleIdList": ["9070662"]}, {"Citation": "Marechal V, Elenbass J, Piette J, Nicolas J, Levine AJ: The ribosomal L5 protein is associated with mdm2 and mdm2 -p53 complexes. Mol Cell Biol 1994, 14:7414-7420", "ArticleIdList": ["PMC359276", "7935455"]}, {"Citation": "Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ: The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996, 2:439-451", "ArticleIdList": ["PMC2230168", "8827714"]}, {"Citation": "Leveillard T, Wasylyk B: The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem 1997, 272:36651-36661", "ArticleIdList": ["9388200"]}, {"Citation": "Daftary DK, Murti PR, Bhonsle RR, Gupta PC, Mehra FS, Pindborg JJ: Risk factors and risk markers for oral cancer in high risk areas of the world. Johnson NW eds. Oral Cancer: The Detection of Patients and Lesions at Risk. 1991, :pp 29-63 Cambridge University Press, Cambridge"}, {"Citation": "Agarwal S, Mathur M, Srivastava A, Ralhan R: MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. Oral Oncol 1999, 35:209-216", "ArticleIdList": ["10435158"]}, {"Citation": "Chomezynski P, Sacchi N: Single-step method of RNA isolation by acid guanidiniumthiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159", "ArticleIdList": ["2440339"]}, {"Citation": "Landers JE, Cassel SL, George DL: Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997, 57:3562-3568", "ArticleIdList": ["9270029"]}, {"Citation": "Heinzel PA, Balaam P, Bernard HO: Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of India betel quid chewers. Int J Cancer 1996, 68:420-423", "ArticleIdList": ["8945609"]}, {"Citation": "Munirajan AK, Tutsumi-Ishii Y, Mohanprasad BKC, Hirano Y, Munakata N, Shanmugan G, Tsuchida N: p53 gene mutations in oral carcinomas from India. Int J Cancer 1996, 66:297-300", "ArticleIdList": ["8621246"]}, {"Citation": "Capoulade C, Bressac-de Paillerets B, Lefrere I, Rpnsin M, Feunteun J, Tursz T, Weils J: Overexpression of MDM2, due to enhanced translation, results in activation of wild-type p53 in Burkitt\u2019s lymphoma cells. Oncogene 1998, 16:1603\u20131610", "ArticleIdList": ["9569028"]}, {"Citation": "Picksley SM, Spicer JF, Barnes DM, Lane DP: The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncol 1996, 35:429-434", "ArticleIdList": ["8695156"]}, {"Citation": "Haines DS, Laners JE, Engle LJ, George DL: Physical and functional interaction between wild-type p53 and MDM2 proteins. Mol Cell Biol 1994, 41:1171-1178", "ArticleIdList": ["PMC358473", "8289798"]}, {"Citation": "Sigalas L, Calvert HA, Anderson JJ, Neal DE, Lunec J: Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996, 2:912-917", "ArticleIdList": ["8705862"]}, {"Citation": "Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue N, Kouzarides T: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995, 375:691-694", "ArticleIdList": ["7791903"]}, {"Citation": "Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698", "ArticleIdList": ["7791904"]}, {"Citation": "Maxwell SA: Selective compartmentalization of different MDM2 proteins within the nucleus. Anticancer Res 1994, 14:2541-2548", "ArticleIdList": ["7872679"]}, {"Citation": "Gorgoulis VG, Zoumpourlist V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, Kittas C: A molecular and immunohistochemical study of MDM2 proteins and p53 gene product in bronchogenic carcinoma. J Pathol 1996, 180:129-137", "ArticleIdList": ["8976869"]}]}], "History": [{"Year": "2000", "Month": "8", "Day": "10", "Hour": "11", "Minute": "0"}, {"Year": "2000", "Month": "8", "Day": "29", "Hour": "11", "Minute": "1"}, {"Year": "2000", "Month": "8", "Day": "10", "Hour": "11", "Minute": "0"}, {"Year": "2001", "Month": "2", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["10934161", "PMC1850135", "10.1016/S0002-9440(10)64569-5", "S0002-9440(10)64569-5"]}}], "PubmedBookArticle": []}